Xtant Medical Holdings Inc. (XTNT) carries a Roarable Rating of C (Hold) with 65/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
As of 2026-11-03, Xtant Medical Holdings Inc. (NYSE: XTNT) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 65/100 at a spot price of $0.28 (-3.51% 1D, market cap $39.3M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 16/20. Across 1016 tracked Health Care issuers, XTNT ranks #121 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), XTNT carries a Roarable C (65/100 RQD), trailing P/E of N/A, gross margin of 62.9%, and ROIC of 12.8%. By comparison, CVRX (CVRx Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $37.6M) and DAVI (Davion Healthcare Plc) posts a D grade (47/100 RQD, P/E N/A, ROIC —, cap $42.0M). Among the 5-stock peer group, SNWV leads on earnings multiple (3.8x) while SNWV leads on capital efficiency (67.3% ROIC).
Per XTNT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001453593), Xtant Medical Holdings Inc. generated $133.9M in revenue (+14.2% YoY), $5.0K in net income, and $10.2M in free cash flow against $94.1M in total assets and $11.0M in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
SEC Form 4 / 13F Thermometer: 80% Net Buy • Cannibal Buyback (-2.36% YoY Shares)
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 37.2 (NEUTRAL RANGE)
Balance-sheet & 10-K footnote risk deducts 8 pts from forensic ceiling
Even with a 65/100 (C) score, XTNT faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
Dilution & Margin Drag: Cannibal Buyback (-2.36% YoY Shares) — any gross margin slip below 60.4% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($0.33) or 200D SMA ($0.46) invalidates the momentum regime and cuts Target Base ($0.29) toward Bear Floor ($0.23).
Xtant Medical Holdings Inc. (XTNT) dropped -3.51% to $0.28, trading at 2% of its 52-week range ($0.27 – $0.89). Solid 63% profit margin (13% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.
Yahoo! Finance Canada report covering Xtant Medical Holdings Inc. (XTNT) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Xtant Medical Holdings Inc. (XTNT) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Xtant Medical Holdings Inc. (XTNT) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Xtant Medical Holdings Inc. (XTNT) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Xtant Medical Holdings Inc. (XTNT) market action, institutional positioning, and fundamental catalysts.
Despite a challenging quarter with declining revenue and margins, Xtant is positioning for growth through the Dillon integration and new product launches targeting a $7.5 billion market.
Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today announced that Sean Browne, CEO, Scott Neils, CFO, and Mark
Yahoo Finance coverage on XTNT stock catalysts, institutional flow, and earnings outlook.
Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today announced that it will release its financial results for th
Moby summary of Xtant Medical Holdings, Inc.'s Q1 2026 earnings call
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +14.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on XTNT today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for XTNT. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Xtant Medical Holdings Inc. (XTNT) ranks #121 by composite RQD confidence (65/100, grade C) and #772 by equity capitalization ($39.3M). Within this direct 5-issuer industry benchmark cohort, SNWV leads on earnings valuation at 3.8x trailing P/E, while SNWV leads on capital efficiency and profitability with 67.3% ROIC and 77.1% gross margin. XTNT currently leads its immediate peer cohort in composite quantitative strength at 65/100 (C).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| XTNT
ACTIVE
Xtant Medical Holdings Inc. | C | 65/100 | — | 62.9% | 12.8% | -3.51% | $39.3M | Benchmark Subject |
| CVRX CVRx Inc. | E | 31/100 | — | 85.3% | -35.0% | -1.05% | $37.6M | /cvrx-vs-xtnt → |
| DAVI Davion Healthcare Plc | D | 47/100 | — | — | — | -37.55% | $42.0M | /davi-vs-xtnt → |
| TELA TELA Bio Inc. | D- | 35/100 | — | 67.7% | -35.0% | -11.95% | $36.6M | /tela-vs-xtnt → |
| SNWV SANUWAVE Health Inc. | D | 51/100 | 3.8x | 77.1% | 67.3% | -2.28% | $44.3M | /snwv-vs-xtnt → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Xtant Medical Holdings Inc. (XTNT) reported GAAP revenue of $133.9M (+14.2% vs. FY2024 revenue of $117.3M , and +46.7% cumulative change since FY2023) , GAAP net income of $5.0K, operating cash flow of $12.5M, and free cash flow of $10.2M (+163.5% YoY). On the balance sheet, XTNT closed FY2025 with $94.1M in total assets against $11.0M in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 9/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $133.9M | $5.0K | $12.5M | $10.2M | $94.1M | $11.0M |
| FY2024 (FY) | 2024-12-31 | $117.3M | -$16.4K | -$11.9M | -$16.0M | $93.8M | $22.0M |
| FY2023 (FY) | 2023-12-31 | $91.3M | $660 | -$9.5M | -$9.5M | — | — |
As of 2026-11-03, Xtant Medical Holdings Inc. (NYSE: XTNT) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 65/100 at a spot price of $0.28 (-3.51% 1D, market cap $39.3M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 16/20. Across 1016 tracked Health Care issuers, XTNT ranks #121 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), XTNT carries a Roarable C (65/100 RQD), trailing P/E of N/A, gross margin of 62.9%, and ROIC of 12.8%. By comparison, CVRX (CVRx Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $37.6M) and DAVI (Davion Healthcare Plc) posts a D grade (47/100 RQD, P/E N/A, ROIC —, cap $42.0M). Among the 5-stock peer group, SNWV leads on earnings multiple (3.8x) while SNWV leads on capital efficiency (67.3% ROIC).
Per XTNT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001453593), Xtant Medical Holdings Inc. generated $133.9M in revenue (+14.2% YoY), $5.0K in net income, and $10.2M in free cash flow against $94.1M in total assets and $11.0M in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.. Institutional options positioning shows a 50% call / 50% put premium split.
XTNT last traded at $0.28 (-3.51% on volume of 44,519 shares), positioning the stock -15.15% below its 50-day simple moving average ($0.33) and -39.13% below its 200-day simple moving average ($0.46). Across its 52-week range of $0.27 to $0.89, XTNT sits at the 1.6% percentile with a 14-day RSI of 37.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.0% ($1.00 to $0.31).
Why XTNT Stock dropped -3.51% Today — RQD Quant Desk Flash. Solid 63% profit margin (13% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.
Per the Roarable RQD rating, XTNT scores 65 out of 100, a letter grade of C, labeled "Roarable Hold — Fair / Balanced Risk-Reward." The five pillars are:
For a prospective investor, the rating signals a mixed picture: cash-flow metrics and insider signals support the stock, while the distress-range Altman score and the sub-dollar price warrant caution. Upside drivers would be sustained FCF generation and continued insider conviction; the main valuation tradeoff is that a low absolute price and small market cap coexist with weak bankruptcy-prediction metrics. The rating is analytical, not a recommendation.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $133.9M | $7.3M | $0.0M | N/A | $10.2M | $17.1M | $11.0M |
| FY 2024 | $117.3M | $-12.1M | $-0.0M | N/A | $-16.0M | $6.2M | $22.0M |
| FY 2023 | $91.3M | $-10.2M | $0.0M | N/A | $-9.5M | N/A | N/A |
Per the SEC financials, revenue grew from $91.3M in FY 2023 to $133.9M in FY 2025, and operating income moved from negative in FY 2023 and FY 2024 to $7.3M in FY 2025. Per the market data, gross margin is 62.9%, operating margin 5.4%, and net margin 0%. ROIC is 12.8%. Per the Roarable RQD rating, the Altman Z-Score is 0.2 (distress range), the Piotroski F-Score is 9/9, and Debt/Equity is 0.22. Debt declined from $22.0M in FY 2024 to $11.0M in FY 2025 while cash rose to $17.1M.
The Butterfly supply-chain graph reports supply_chain as NONE, with no butterfly links and no proprietary signals.
Real-time company headlines, analyst actions, and sector developments for Xtant Medical Holdings Inc. (XTNT) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo! Finance Canada report covering Xtant Medical Holdings Inc. (XTNT) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Xtant Medical Holdings Inc. (XTNT) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Xtant Medical Holdings Inc. (XTNT) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Xtant Medical Holdings Inc. (XTNT) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Xtant Medical Holdings Inc. (XTNT) market action, institutional positioning, and fundamental catalysts.
Despite a challenging quarter with declining revenue and margins, Xtant is positioning for growth through the Dillon integration and new product launches targeting a $7.5 billion market.
Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today announced that Sean Browne, CEO, Scott Neils, CFO, and Mark
Yahoo Finance coverage on XTNT stock catalysts, institutional flow, and earnings outlook.
Welcome to the XTNT (Xtant Medical Holdings Inc.) Roar Pit. Current RQD Composite is 65/100 (Roarable Hold — Fair / Balanced Risk-Reward) in Medical/Dental Instruments. Bulls point to capital efficiency (12.8% ROIC), while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on XTNT, but look at what you are paying: current EV/EBITDA multiples with 62.9% gross margins. Unless Xtant Medical Holdings Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on XTNT, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $0.29 (52-wk range $0.27 - $0.95), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).